GRB14 CRISPR Activation Plasmid (h): sc-405224-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GRB14 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GRB14 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GRB14 CRISPR Activation Plasmid (h) and GRB14 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GRB14 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GRB14 CRISPR Activation Plasmid (h) | sc-405224-ACT | 20 µg | $397.00 |
GRB14 (growth factor receptor-bound protein 14) is an adaptor protein that binds activated receptor tyrosine kinases and modulates downstream signal transduction, with well-characterized interactions affecting insulin receptor and IGF1R signaling. By engaging with signaling complexes at the plasma membrane, GRB14 can influence PI3K–AKT and MAPK pathway output, shaping cellular metabolism, proliferation, and survival programs. Altered GRB14 expression or activity has been linked to dysregulated insulin signaling and metabolic phenotypes, and its pathway positioning also makes it relevant to growth factor–dependent cellular states studied in cancer biology. Experimental modulation of GRB14 supports mechanistic work on receptor proximal signaling, feedback control, and pathway cross-talk in human cell models.
GRB14 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GRB14 expression without altering the underlying DNA sequence.
GRB14 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GRB14 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GRB14 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GRB14 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GRB14 locus and enabling the study of GRB14-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GRB14 pathway restoration in tumor cells with silenced or reduced GRB14 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.